GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Cubicin® | LY-146032 | LY146032
daptomycin is an approved drug (FDA (2003), EMA (2006))
Compound class:
Natural product
Comment: Daptomycin is a cyclic lipopeptide antibacterial with broad-spectrum activity against Gram-positive bacteria [2]. It is a bacterial metabolite that was isolated from Streptomyces roseosporus [1]. Daptomycin rapidly depolarizes the bacterial cell membrane which disrupts DNA, RNA and protein synthesis and results in cell death.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Debono M, Barnhart M, Carrell CB, Hoffmann JA, Occolowitz JL, Abbott BJ, Fukuda DS, Hamill RL, Biemann K, Herlihy WC. (1987)
A21978C, a complex of new acidic peptide antibiotics: isolation, chemistry, and mass spectral structure elucidation. J Antibiot (Tokyo), 40 (6): 761-77. [PMID:3610833] |
|
2. Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering Jr RC. (1986)
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother, 30 (4): 532-5. [PMID:3024560] |
|
3. Ge Y, Biek D, Talbot GH, Sahm DF. (2008)
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother, 52 (9): 3398-407. [PMID:18625769] |
|
4. World Health Organization. Regional Office for Europe.
Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for Children (EMLc): Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics. Accessed on 08/05/2026. Modified on 08/05/2026. https://iris.who.int/items/e2f730ae-f66f-44d6-bc24-164fe79164ec |